Ivarmacitinib Treat PMR (ESI-PMR)

November 12, 2026 updated by: Weiqian Chen, Zhejiang University

Efficacy and Safety of Ivarmacitinib for Polymyalgia Rheumatica (ESI-PMR): A 52-Week Open-Label, Randomized, Controlled Clinical Trial

To evaluate the efficacy of the combination of Ivarmacitinib and short-term glucocorticoid induction for remission and rapid discontinuation of glucocorticoids in the treatment of Polymyalgia rheumatica (PMR) , and to compare the differences in the proportion of patients in remission at weeks 24 between the experimental group and control group.

Study Overview

Status

Not yet recruiting

Detailed Description

PMR is a common inflammatory disorder in older adults (aged >50 years), characterized by pain and stiffness in the neck, shoulder girdle, and pelvic girdle. Systemic glucocorticoid administration is the current standard of care, achieving rapid control of inflammation and symptom alleviation. However, standard regimens require prolonged administration (at least 12 months) and are associated with a high rate of relapse during steroid tapering. In this vulnerable population with a high burden of baseline chronic comorbidities (e.g., osteoporosis, diabetes, cardiovascular disease), sustained glucocorticoid use frequently leads to severe adverse effects, such as steroid-induced osteoporosis, peptic ulceration, hyperglycemia, glaucoma, opportunistic infections, and metabolic dysregulation. Consequently, there is an urgent need to explore safer, more effective, and more accessible therapeutic strategies.

Ivarmacitinib, a highly selective JAK1 inhibitor, is approved for rheumatoid arthritis and ankylosing spondylitis, but remains unapproved for PMR. Thus, this protocol represents an investigator-initiated off-label study. Accumulated evidence indicates that JAK1 inhibition holds substantial potential for controlling PMR disease activity and facilitating steroid tapering. To address the current lack of high-level clinical evidence, this study was initiated to assess the 52-week efficacy and safety of ivarmacitinib in patients with PMR.

Study Type

Interventional

Enrollment (Estimated)

144

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Weiqian Chen Dr. Chen, Doctor
  • Phone Number: 860571-87233418
  • Email: cwq678@zju.edu.cn

Study Contact Backup

  • Name: Xinxin Han Dr. Han, Doctor
  • Phone Number: 860571-87233418
  • Email: hxx1992@126.com

Study Locations

    • Zhejiang
      • Anji, Zhejiang, China
        • Anji People's Hospital
        • Contact:
      • Haining, Zhejiang, China
        • Haining Kanghua Hospital
        • Contact:
          • Jiantao Sun Dr. Sun
          • Phone Number: +8615967333501
          • Email: 5598338@qq.com
      • Hangzhou, Zhejiang, China
        • the First Affiliated Hospital, Zhejiang University School of Medicine
        • Contact:
          • Weiqian Chen Dr. Chen, Doctor
          • Phone Number: 860571-87233418
          • Email: cwq678@zju.edu.cn
      • Huzhou, Zhejiang, China
        • Huzhou First People's Hospital
        • Contact:
      • Wenzhou, Zhejiang, China
        • Wenzhou People's Hospital
        • Contact:
          • Suxian Lin Dr. Lin
          • Phone Number: 8613957741565
          • Email: 4268945@qq.com
      • Yiwu, Zhejiang, China
        • the Fourth Affiliated Hospital, Zhejiang University School of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 88 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. patients who fulfilled the 2012ACR/EULAR criteria for PMR;
  2. Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS > 10,
  3. Adults age 50-88, Weight 45-85Kg,
  4. ESR>40mm/h or CRP >50mg/L(5mg/dl),
  5. Informed consent.

Exclusion Criteria:

  1. Patients with known allergies to Ivarmacitinib, prednisone or methylprednisolone,
  2. Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,
  3. Patients with severe osteoarthritis,
  4. Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),
  5. Hepatitis B virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, HIV infection,
  6. Patients with abnormal liver function (ALT/AST 2 times higher); Moderate to severe renal impairment (glomerular filtration rate <60); hyperlipidemia not improved by lipid-lowering drugs,
  7. Pregnant or lactating women,
  8. Patients with a history of malignancy who do not meet the following condition (patients with malignant tumors who have been successfully treated for more than 5 years before screening without any evidence of recurrence),
  9. Patients with previous visual field disorder or single eye dysfunction, cataract patients,
  10. Patients with decompensated cardiac insufficiency or severe hypertension or diabetes mellitus, i.e. systolic blood pressure higher than 160mmhg or diastolic blood pressure higher than 100mmhg,
  11. For patients with abnormal blood routine, lymphocytes <500/mm3 or ANC <1000/mm3 or HGB < 90g/L,
  12. Patients with active bleeding and peptic ulcer,
  13. Have used biological agents or added azathioprine, FK506 within 1 month before enrollment,
  14. Those who have participated in other drug clinical trials within 4 weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ivarmacitinib

Withdrawal of prednisone within 8 weeks: 15mg daily for 2 weeks, 10mg daily for 4 weeks, 5mg daily for 2 weeks, then discontinue; Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks.

Withdrawal of prednisone within 8 weeks. Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks.

Active Comparator: Prednisone

Prednisone 15mg daily was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-8 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 10 weeks. Once relapse occurred, the dose increased to the pre-relapse dose.

The dose of Prednisone was gradually tapered. Once relapse occurred, the dose increased to the pre-relapse dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients in remission at weeks 24
Time Frame: at weeks 24

Proportion of patients in remission at weeks 24

at weeks 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients in remission at weeks 52
Time Frame: at weeks 52

Proportion of patients in remission at weeks 52

at weeks 52
PMR-AS score at weeks 24
Time Frame: at weeks 24

PMR-AS score: CRP (mg/dL)+Patient self-evaluation (0-10 visual scale)+ Physician global assessment (0-10 Visual Scale)+[morning stiffness (min) x0.1]+ EUL (0-3).

at weeks 24
CRP at weeks 24
Time Frame: at weeks 24

CRP at weeks 24

at weeks 24
ESR at weeks 24
Time Frame: at weeks 24

ESR at weeks 24

at weeks 24
Relapse rate within 52 weeks
Time Frame: within 52 weeks

Relapse rate within 52 weeks

within 52 weeks
Relapse times within 52 weeks
Time Frame: within 52 weeks

Relapse times within 52 weeks

within 52 weeks
Cumulative dose of prednisone within 52 weeks
Time Frame: within 52 weeks

Cumulative dose of prednisone within 52 weeks

within 52 weeks
Cumulative dose of MTX within 52 weeks
Time Frame: within 52 weeks

Cumulative dose of MTX within 52 weeks

within 52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Jin Lin, Prof., First Affiliated Hospital of Zhejiang University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

March 30, 2028

Study Completion (Estimated)

December 30, 2028

Study Registration Dates

First Submitted

November 4, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Due to the policies of the country, it is not possible to directly share the personal data of the subjects. If the researchers are interested, they can contact the relevant person via email to obtain the summarized data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe